For people living with type 1 diabetes, new treatments may be finally on the horizon. Paresh Dandona, MD, PhD
, SUNY Distinguished Professor of medicine
and chief of endocrinology, diabetes and metabolism
, describes how the University at Buffalo Endocrinology Research Center is helping to revolutionize the treatment of this condition. He explains why two non-insulin medications currently used in type 2 diabetes, SGLT-2 inhibitors and GLP-1 receptor agonists, are among the most promising new therapies. “The hope is that non-insulin therapies will soon be approved for type 1 diabetes. By unlocking the potential of these therapies, we can do more than manage blood glucose levels – we can improve people’s lives,” writes Dandona.